However, long-term persistence of the anti–PD-1 CAR was associated with CAR-mediated immunodeficiency and lymphopenia, indicating a need for improved CAR design with additional layers of safety to ablate CAR T cell activity in vivo. Here, PDCD1 is linked to immune system disorder.